We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Vaping hub (19)
- Compliance and enforcement (18)
- Advertising (16)
- Legislation (15)
- Safety monitoring and information (12)
- Manufacturing (11)
- COVID-19 (8)
- Import and export (8)
- Labelling and packaging (8)
- Medicinal cannabis hub (6)
- Scheduling (national classification system) (5)
- Weight loss products (3)
- Clinical trials (2)
- Committees and advisory bodies (1)
- Fees and payments (1)
- Shortages and supply disruptions (1)
- Sunscreens (1)
Search
119 result(s) found, displaying 1 to 25
-
News articlesRecall reforms program update and preview of the PRAC Version 1.0.
-
Media releasesWe have issued infringement notices totalling $37,560 for the alleged unlawful possession of a commercial quantity of vaping goods.
-
Safety updatesTCMs sold in Australia are carefully regulated to ensure safety and quality.
-
Media releasesThe TGA and cooperating agencies have seized a large volume of alleged illicit vapes, tobacco and other substances in coordinated operations across Australia.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
News articlesFind out about new requirements for labels of injectable electrolyte medicines and updates to guidance for medicine sponsors.
-
Regulatory decision noticesMRA GMP clearances that are expiring on 31 December 2024 will be automatically extended.
-
BlogIf your business sells or advertises paracetamol, then you need to be aware of the new rules around pack sizes that commence on 1 February 2025.
-
BlogWe know that paracetamol is safe and effective for most people when taken at the recommended dose.
-
Regulatory decision noticesThis instrument is made under section 39 of the current Poisons Standard.
-
Regulatory decision noticesThis instrument is made under section 39 of the current Poisons Standard.
-
Regulatory decision noticesWe are providing a 12-month period of labelling exemptions for signal words for certain Pharmacy medicine and Pharmacist Only medicine products.
-
News articlesWe have introduced new features to improve your experience using Guidance on our website.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesHealth professionals and consumers are advised that the oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be used in children under 6 years of age.
-
Media releasesThe TGA has settled judicial review proceedings brought by InstantScripts in respect of infringement notices issued to it by the TGA.
-
Media releasesIn a significant move against the illicit vaping market, the TGA has played a vital role in joint enforcement activity with Victoria Police, resulting in the seizure of 200,000 vapes, worth more than $8 million
-
Safety updatesWe have received Australian reports of Guillain-Barré Syndrome (GBS) following Shingrix vaccination.
-
Media releasesTGA has taken further action to combat the unlawful sale of vapes in Queensland, issuing an infringement notice to a retailer for the unlawful possession of a commercial quantity of vaping goods
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Media releasesThe TGA worked alongside Victoria Police officers as part of an ongoing investigation targeting a significant crime syndicate involved in the illicit tobacco market.
-
Media releasesThe 3G network shutdown may impact certain medical devices. Consumers, healthcare providers, manufacturers, and suppliers should take precautions to prevent disruption in essential medical services.
-
Media releasesWe are aware of misinformation that claims the COVID-19 mRNA vaccines are contaminated with excessive levels of DNA. This is not the case.
-
News articlesTGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease).
-
News articlesThe TGA is updating information for nitrosamine impurities in medicines including acceptable intakes (AI).